Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas Ligand pathway

Molecular Mechanism of MART-1 + /A*0201 + Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction

(2010) Ali R. Jazirehi et al.   CANCER RESEARCH

Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy

(2010) Robert M. Prins et al.   CLINICAL CANCER RESEARCH

Developments in Cancer Immunotherapy

(2010) Maries van den Broek et al.   DIGESTIVE DISEASES

Distinct roles of cytolytic effector molecules for antigen-restricted killing by CTL in vivo

(2010) Edith M Janssen et al.   IMMUNOLOGY AND CELL BIOLOGY

Survival comparison between glioblastoma multiforme and other incurable cancers

(2010) B. Tran et al.   JOURNAL OF CLINICAL NEUROSCIENCE

The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells

(2010) Maika Almstedt et al.   LEUKEMIA RESEARCH

Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics

(2010) Camilla Krakstad et al.   Molecular Cancer

Cancer/testis (CT) antigens: Potential targets for immunotherapy

(2009) Otavia L. Caballero et al.   CANCER SCIENCE

Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen

(2009) J. A. Dubovsky et al.   CLINICAL CANCER RESEARCH

Modular Nucleic Acid Assembled p/MHC Microarrays for Multiplexed Sorting of Antigen-Specific T Cells

(2009) Gabriel A. Kwong et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma

(2008) Atsushi Natsume et al.   INTERNATIONAL JOURNAL OF CANCER